[HTML] nejm.org

[HTML][HTML] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021 - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
被引用次数：422 相关文章
[PDF] uclouvain.be

[PDF][PDF] A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu, QM Anstee… - N Engl J …, 2021 - dial.uclouvain.be
BACKGROUND Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical
need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

SM Francque, P Bedossa, V Ratziu… - The New England …, 2021 - europepmc.org
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that …

[引用][C] A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu, QM Anstee… - NEW ENGLAND …, 2021 - iris.unito.it

[引用][C] A Randomized Controlled Trial of the PanPPAR Agonist Lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu… - New England Journal …, 2021 - eprints.ncl.ac.uk
BACKGROUND Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical
need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu… - The New England …, 2021 - repository.uantwerpen.be
A Randomized Trial of a Pan-PPAR Agonist in NASH Lanifibranor is a pan-peroxisome
proliferator-activated receptor agonist that modulates metabolic and inflammatory pathways …

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

S Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021 - univ-angers.hal.science
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH - Université
d'Angers Accéder directement au contenu Documentation FR Se connecter Portail HAL UA …

[引用][C] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH

S Francque, P Bedossa, V Ratziu… - The New England …, 2021 - difusion.ulb.ac.be

A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH

SM Francque, P Bedossa, V Ratziu… - The New England …, 2021 - research.monash.edu
BACKGROUND Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical
need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH

SM Francque, P Bedossa… - The New …, 2021 - research-repository.uwa.edu.au
Background: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that …